<- Go Home
Urologix, Inc.
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.
Market Cap
$21.00
Volume
35.5K
Cash and Equivalents
$492.0K
EBITDA
-$373.0K
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$5.7M
Profit Margin
47.13%
52 Week High
$0.00
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
-0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$874.0K
Return on Equity
80.78%
Return on Assets
-7.62
Cash and Short Term Investments
$492.0K
Debt
$5.3M
Equity
-$8.1M
Revenue
$12.0M
Unlevered FCF
$1.2M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium